Ganaxolone shows positive phase 2 results in TSC-related epilespy
Marinus Pharmaceuticals has released positive initial results of ganaxolone in TSC-related epilepsy, with the phase 2 trial demonstrating a reduction in seizure frequency in people living with TSC-related epilepsy. The encouraging findings pave way for a larger study of the medicine, expected to begin